Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Conjugate Salmonella typhi Vi vaccine has high efficacy in young children

The Salmonella typhi Vi conjugate typhoid vaccine is safe and immunogenic, and has more than 90% efficacy in children 2 to 5 years old, according to research published in the latest issue of the New England Journal of Medicine.

News image

fiogf49gjkf04

A team from Vietnam and the USA evaluated the safety, immunogenicity, and efficacy of the Salmonella typhi Vi conjugate vaccine in children 2 to 5 years old.

The newly devised vaccine is a conjugate of the capsular polysaccharide of Salmonella typhi , Vi, bound to nontoxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA). It has enhanced immunogenicity in adults and in children 5 to 14 years old, and has elicited a booster response in children 2 to 4 years old.

A total of 11,091 children from 16 communities in the Dong Thap Province, Vietnam were enrolled in the double-blind, randomized trial.

Each subject received 2 injections, 6 weeks apart, of either Vi-rEPA or a saline placebo.

Cases of typhoid, diagnosed by the isolation of S. typhi from blood cultures after 3 or more days of fever (a temperature of 37.5°C or higher), were identified by active surveillance over a period of 27 months.

The researchers estimated efficacy by comparing the attack rates of typhoid in the vaccine group with that in the placebo's group.

The efficacy of the Vi-rEPA conjugate vaccine is 92%.
New England Journal of Medicine

S. typhi was isolated from 4 of the 5,525 children who were fully vaccinated with Vi-rEPA and from 47 of the 5,566 children who received both injections of placebo. From these figures, the authors calculated the efficacy to be 92%.

Among the 771 children who received only one injection, there was 1 case of typhoid in the vaccine group and 8 cases in the placebo group.

Cases were distributed evenly among all age groups and throughout the study period. No serious adverse reactions were observed.

In all 36 children studied 4 weeks after the second injection of the vaccine, the researchers found that levels of serum IgG Vi antibodies had increased by a factor of 10 or more.

Dr Feng Ying C. Lin, of the National Institute of Child Health and Human Development, Bethesda, Maryland, concluded on behalf of the group, "The Vi-rEPA conjugate typhoid vaccine is safe and immunogenic and has more than 90% efficacy in children 2 to 5 years old.

"The antibody responses and the efficacy suggest that this vaccine should be at least as protective in persons who are more than five years old."

N Engl J Med 2001; 344: 1263-9
30 April 2001

Go to top of page Email this page Email this page to a colleague

 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us